Information Provided By:
Fly News Breaks for February 7, 2019
SLDB, SRPT
Feb 7, 2019 | 15:05 EDT
After Solid Biosciences (SLDB) reported preliminary patient biopsy data with SGT-001, the company's AAV9 microdystrophin gene therapy, Piper Jaffray analyst Danielle Brill said she expected significantly lower expression levels than Sarepta (SRPT) generated, but the "dismal expression" reported is particularly concerning as it suggests lack of efficacy may be driven by something other than a sub-therapeutic dose. She also believes pushing the dose high enough to compete on efficacy could be a challenge given the safety profile of SGT-001. She views today's news as a "considerable setback" for Solid and believes it strengthens Sarepta's "front-runner position," Brill tells investors. She maintains an Overweight rating and $200 price target on Sarepta shares.